Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-23T12:00:34.533Z Has data issue: false hasContentIssue false
  • English
  • Français

Chemotherapy in Polycythemia Vera*

Published online by Cambridge University Press:  01 August 2014

G. Stecher  and
G. Reinhardt
G. Stecher
Affiliation:
Forschungsgruppe Freiburg, Institut Für Hämatologie der GSF, Assoziation mit Euratom, Freiburg/Breisgau, Medizinische Universitäts-Poliklinik, Köln
G. Reinhardt
Affiliation:
Forschungsgruppe Freiburg, Institut Für Hämatologie der GSF, Assoziation mit Euratom, Freiburg/Breisgau, Medizinische Universitäts-Poliklinik, Köln

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

210 cases of polycythemia vera were observed over a period of 15 years. The majority of them received P32; treatment with Myleran instead of with radioactive phosphorus was instituted only recently. To a small number of patients chemotherapy was given alternately with P32. The differing response pattern to either kind of treatment and the possible interference of therapy with the natural development of the disease process are demonstrated in a few selected cases.

Type
Research Article
Information
Acta geneticae medicae et gemellologiae: twin research , Volume 17 , Issue 1 , January 1968 , pp. 292 - 302
Copyright
Copyright © The International Society for Twin Studies 1968

Footnotes

*

Research supported in part by the Association Contract “Hematology” between the GSF and Euratom.

References

Braunsteiner, H., Sailer, S. (1961). Erythrozythämie im Verlaufe einer chronischen myeloischen Leukämie. Wien. Z. Inn. Med., 42: 10–12.Google Scholar
Calabresi, P. (1958). Myeloproliferative syndrome with leukemia preceding polycythemia vera: a case report. Blood, 13: 642–651.Google Scholar
Hunstein, W. et. al. (1965). Bioptische Untersuchungen zur Frage der therapiebedingten Knochenmarkfibrosen bei der chronischen myeloischen Leukämie. Med. Klin., 60: 991–995.Google Scholar
Hunstein, W. et al. (1966). Bioptische Untersuchungen zur frage der Faservermehrung in Knochenmark bei p32 - behandelter Polycythaemia vera. Congr. German Soc. Int. Med., Wiesbaden 1966 (Abstract).Google Scholar
Killmann, S. A., Cronkite, E. P. (1961). Treatment of polycythemia vera with myrelan. Amer. J. Med. Sci., 241: 218–244.CrossRefGoogle Scholar
Lopaz, H., Josephson, A M. (1964). Myeloproliferative syndrome. Evaluation of myelosclerosis and chronic myelogenous leukemia to polycythemia vera. Arch. Intern. Med., 114: 754–759.Google Scholar
Louis, J. (1958). Treatment of polycythemia vera with busulfan (myleran). J.A.M.A., 168: 1880–1882.Google Scholar
Modan, B., Lilienfeld, A. (1965). Leukaemogenic effect of ionising-irradiation treatment in polycythemia. Lancet. 1: 607–608.Google Scholar
Perkins, J. et al. (1964). Polycythaemia vera: clinical studies on a series of 127 patients managed without radiation therapy. Quart. J. Med., New Series, 33: 499–518.Google Scholar
Stecher, G. et al. (1961). Polycythaemia vera. Deutsch. Med. Wschr., 86: 1861–1899.CrossRefGoogle Scholar
Wald, N. et al. (1958). Therapy of polycythemia vera with myleran. Blood, 13: 757.CrossRefGoogle ScholarPubMed